Indications for use of Phosphogliv are:

• fatty liver degeneration (hepatosis);
•  other liver damage (alcoholic, toxic, including medicinal); 
• as part of the complex therapy of viral hepatitis, liver cirrhosis, and psoriasis.

Pharmachologic effect:

Combined drug.

It has membrane stabilizing, hepatoprotective and antiviral effects. Phosphatidylcholine (the active substance of phospholipids) is the main structural element of cellular and intracellular membranes, is able to restore their structure and function in case of damage, providing a cytoprotective effect. It normalizes protein and lipid metabolism, prevents the loss of enzymes and other active substances by hepatocytes, restores the detoxifying function of the liver, inhibits the formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis. Glycyrate (glycyrrhizic acid and salts) has an anti-inflammatory effect, inhibits the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, and increasing the activity of natural killer cells. It has a hepatoprotective effect due to antioxidant and membrane stabilizing activity. It potentiates the action of endogenous glucocorticosteroids, providing anti-inflammatory and anti-allergic effects in non-infectious liver damage. In case of skin lesions due to the membrane-stabilizing and anti-inflammatory action of the components, it limits the spread of the process and contributes to the regression of the disease.

Pharmacokinetics:

Phosphatidylcholine:

More than 90% of the phospholipids taken orally are absorbed from the small intestine. Most of it is cleaved by phospholipase A to 1-acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. Polyunsaturated phosphatidylcholine with the lymph flow enters the bloodstream, from where, mainly in the form associated with high density lipoproteins, it enters the liver. Pharmacokinetics in humans was studied using radioactively labeled dilenoleylphosphatidylcholine - 3H (choline part) and 14C (linoleic acid residue). Cmax 3H is achieved in 6-24 hours, accounting for 19.9% ​​of the prescribed dose; 14C - after 4-12 hours, accounting for 27.9%. T1 / 2 of the choline component is 66 hours, the remainder of linoleic acid - 32 hours. In feces, 2% 3H and 4.5% - 14C are found; in urine - 6% 3H and a minimum amount of 14C. Both isotopes are absorbed in the intestine by more than 90%. Glycyrrhizic acid After ingestion in the intestine under the influence of the β-glucuronidase enzyme produced by bacteria of normal microflora, an active metabolite, β-glycyrrhetic acid, is formed from glycyrrhizic acid, which is absorbed into the systemic circulation. In the blood, β-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Excretion of β-glycyrrhetic acid occurs mainly with bile, in the residual amount - with urine. According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2 times.